Ganeden Biotech announced that a new study has been published in the peer-reviewed publication, AIDS Research and Human Retroviruses. The study was a randomised, double blind and placebo controlled trial in HIV positive subjects who consumed either 2 billion CFU of GanedenBC30 daily or a matching placebo for 90 days.
This study demonstrated that GanedenBC30 supports both digestive and immune health in HIV subjects. The study also provided additional evidence that even in an immune-compromised subject group, there is an absence of safety concerns when consuming GanedenBC30 on a daily basis.
"HIV infection has a profound impact on the gastrointestinal immune system, which many scientists believe to be central to the development of AIDS,” adds Dr. Otto Yang, Scientific Director of the AIDS Healthcare Foundation and Professor, Associate Chief of Infectious Diseases at UCLA. “This study demonstrates that probiotics may be a means to beneficially support the GI immune system in HIV subjects."
“This research further builds on the science supporting the benefits of GanedenBC30,” said David Keller, VP of Scientific Operations at Ganeden Biotech. “Now not only do we have data that GanedenBC30 is safe for individuals with a healthy immune system, but this study provides evidence which supports safety in an immune-compromised population.”